Medivation Inc. Has so far resisted overtures from Paris-based Sanofi, which is seeking to compete with the likes of America's Bristol-Myers Squibb, Switzerland's Roche and Britain's AstraZeneca, all three of whom have poured money into cancer drug research.
Sanofi Chief Executive Olivier Brandicourt says in an open letter to Medivation's CEO David T Hung that the all-cash offer is for USD 52.50 per share. He says that the deal would give Medivation's cancer treatments the benefit of Sanofi's "global capabilities (and) significant resources."